

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2026 FIRST QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the first quarterly report of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the financial year 2026. This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, April 28, 2026

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive directors of the Company are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.

HANGZHOU TIGERMED CONSULTING CO., LTD.

2026 First Quarterly Report

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and there is no false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The Board of Directors, Directors and senior management warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.
2. The head of the Company, person-in-charge of accounting affairs and head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
3. Whether the first-quarter financial and accounting report is audited
 Yes No

I. KEY FINANCIAL DATA

(I) Major accounting data and financial indicators

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

Yes No

	Reporting Period	Prior Period	Change (%)
Revenue (RMB)	1,801,473,935.03	1,564,143,614.71	15.17%
Net profit attributable to shareholders of the listed company (RMB)	49,043,121.13	165,468,741.43	-70.36%
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss (RMB)	120,394,081.64	102,328,863.87	17.65%
Net cash flows from operating activities (RMB)	317,703,776.36	197,934,614.18	60.51%
Basic earnings per share (RMB/share)	0.06	0.19	-68.42%
Diluted earnings per share (RMB/share)	0.06	0.19	-68.42%
Weighted average return on net assets	0.23%	0.80%	-0.57%

	End of the Reporting Period	End of prior year	Change (%)
Total assets (RMB)	28,800,484,800.80	28,358,795,158.17	1.56%
Owners' equity attributable to shareholders of the listed company (RMB)	20,916,402,606.45	20,959,506,514.77	-0.21%

(II) Items and amounts of extraordinary gain or loss Applicable Not applicable*Unit: RMB*

Item	Amount for the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for asset impairment)	-463,466.46	Mainly due to the disposal of long-term assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business scope of the Company and entitled in defined standard in conformity with the provisions of policies of the State and that have a sustained impact on the Company's profit or loss) included in the profit or loss for the period	18,906,204.73	Mainly due to the government grants received by the Company during the Reporting Period.
Profit or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial companies and profit or loss arising from the disposal of financial assets and financial liabilities (except for those related to effective hedging businesses under ordinary business scope of the Company)	205,977,784.15	Mainly due to gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Gain or loss from investments on trust or asset management	11,083,900.76	Mainly due to the income from wealth management products of the Company during the Reporting Period.
Other non-operating income and expenses apart from the above items	105,780.22	
Less: Effect of income tax	38,011,763.42	
Effect of minority interests (after tax)	268,949,400.49	Mainly due to the increase in the fair value of other non-current financial assets held by the Company's non-wholly-owned subsidiaries during the reporting period.
Total	-71,350,960.51	-

Details of other profit or loss items meeting the definition of extraordinary gain or loss

Applicable Not applicable

There was no other profit or loss items that met the definition of extraordinary gain or loss.

Explanation on extraordinary gain or loss items defined as recurring gain or loss items as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss

Applicable Not applicable

There was no item of extraordinary gain or loss defined as item of recurring gain or loss as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss.

(III) Changes in key accounting data and financial indicators and the reasons thereof

Applicable Not applicable

1. Explanation of anomalies for balance sheet items and the reasons thereof

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Financial assets held for trading	32,707,444.17	59,459,161.12	-44.99%	Mainly due to the maturity of the Company's wealth management products during the Reporting Period.
Inventories	55,950,637.88	41,501,796.41	34.81%	Mainly due to the Company's procurement of raw materials during the Reporting Period.
Long-term borrowings	691,647,009.48	510,560,589.95	35.47%	Mainly due to the long-term borrowings obtained by the Company during the Reporting Period.
Long-term payables	11,980,000.00	102,518,850.00	-88.31%	Mainly due to the payment of equity acquisition consideration by the Company during the Reporting Period.

2. Explanation of anomalies for income statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Other income	20,766,535.53	12,907,751.88	60.88%	Mainly due to the increase in government grants received by the Company during the Reporting Period.
Investment income	36,660,390.11	25,309,680.34	44.85%	Mainly due to the increase in investment income from long-term equity investments accounted for using the equity method during the Reporting Period.
Gain from changes in fair value	195,035,877.15	-22,391,786.77	Not applicable	Mainly due to the increase in gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-2,488,564.14	-11,100,193.38	-77.58%	Mainly due to the decrease in bad debt provision for accounts receivable made by the Company during the Reporting Period.
Asset impairment loss	-572,928.54	-3,523,796.53	-83.74%	Mainly due to the decrease in bad debt provision for contract assets made by the Company during the Reporting Period.
Gain on disposal of assets	-463,466.46	577,115.15	Not applicable	Mainly due to losses incurred from the disposal of non-current assets by the Company during the reporting period.

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Non-operating expenses	27,742.70	1,038,576.02	-97.33%	Mainly due to the decrease in expenses of donations by the Company during the Reporting Period.
Income tax expenses	75,860,662.83	33,644,494.98	125.48%	Mainly due to the year-on-year increase in the profit before tax of the Company during the Reporting Period.

3. *Explanation of anomalies for cash flow statement items and the reasons thereof*

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Net cash flows from operating activities	317,703,776.36	197,934,614.18	60.51%	Mainly due to the increase in net inflow from the Company's operating activities as a result of deducting the cash paid for goods and services from the cash received from sale of goods or rendering of services during the Reporting Period.
Net cash flows from investing activities	54,236,255.84	-657,869,238.36	Not applicable	Mainly due to the Company's redemption of wealth management products and dividends from associates during the Reporting Period.
Net cash flows from financing activities	7,575,168.09	-103,865,806.50	Not applicable	Mainly due to the decrease in cash payments for other activities related to financing activities by the Company during the reporting period.

II. SHAREHOLDERS' INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored and the shareholding of top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	50,049	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	0
---	--------	---	---

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage (%)	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares	
					Share status	Quantity
Ye Xiaoping	Domestic natural person	20.58%	177,239,541	132,929,656	Not applicable	0
HKSCC NOMINEES LIMITED	Overseas legal person	14.30%	123,119,129	0	Not applicable	0
Hong Kong Securities Clearing Company Limited	Overseas legal person	6.01%	51,708,882	0	Not applicable	0
Cao Xiaochun	Domestic natural person	5.96%	51,314,174	38,485,630	Pledged	20,000,000
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	3.09%	26,644,313	0	Not applicable	0
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	Others	2.08%	17,939,470	0	Not applicable	0
China Everbright Bank Company Limited – AegonIndustrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	Others	1.39%	11,987,897	0	Not applicable	0
Shi Xiaoli	Domestic natural person	1.13%	9,700,980	0	Pledged	1,326,949

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage (%)	Number of shares held	Number of shares held subject to selling restrictions		Situation of pledged, marked or frozen shares Share status	Quantity
China Merchants Bank Co., Ltd.-AIFMC Herun Hybrid Securities Investment Fund	Others	1.04%	8,996,496	0	0	Not applicable	0
National Social Security Fund Portfolio 601	Others	0.99%	8,506,534	0	0	Not applicable	0

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares held not subject to selling restrictions	Class of shares		Quantity
		Class of shares		
HKSCC NOMINEES LIMITED	123,119,129	Overseas listed foreign shares		123,119,129
Hong Kong Securities Clearing Company Limited	51,708,882	Renminbi ordinary shares		51,708,882
Ye Xiaoping	44,309,885	Renminbi ordinary shares		44,309,885
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	26,644,313	Renminbi ordinary shares		26,644,313
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	17,939,470	Renminbi ordinary shares		17,939,470
Cao Xiaochun	12,828,544	Renminbi ordinary shares		12,828,544
China Everbright Bank Company Limited – AegonIndustrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	11,987,897	Renminbi ordinary shares		11,987,897
Shi Xiaoli	9,700,980	Renminbi ordinary shares		9,700,980
China Merchants Bank Co., Ltd.-AIFMC Herun Hybrid Securities Investment Fund	8,996,496	Renminbi ordinary shares		8,996,496
National Social Security Fund Portfolio 601	8,506,534	Renminbi ordinary shares		8,506,534

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares	Class of shares	Quantity
	held not subject to selling restrictions	Class of shares	

Explanation of the shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.		
--	---	--	--

Description of top 10 shareholders participating in the margin trading business (if any)	Nil		
--	-----	--	--

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions participating in lending shares through shares lending and refinancing business

Applicable Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions compared with the previous period due to lending/returning shares through shares lending and refinancing

Applicable Not applicable

(II) Total number of preferred shareholders of the Company and the shareholding of top 10 preferred shareholders

Applicable Not applicable

(III) Changes in restricted shares

Applicable Not applicable

Unit: share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares unlocked during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Cao Xiaochun	38,746,330	260,700	0	38,485,630	lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Li Xiaori	11,058	0	0	11,058	lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Total	171,687,044	260,700	0	171,426,344	-	-

III. OTHER SIGNIFICANT EVENTS

Applicable Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) FINANCIAL STATEMENTS

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

March 31, 2026

Unit: RMB

Item	Closing balance	Opening balance
Current assets:		
Cash at bank and on hand	2,168,149,586.04	1,777,491,807.26
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	32,707,444.17	59,459,161.12
Derivative financial assets		
Notes receivable	9,275,011.92	7,004,266.15
Accounts receivable	1,360,243,269.51	1,405,728,258.63
Accounts receivable financing	1,239,061.49	3,953,348.43
Advances to suppliers	121,535,508.28	122,972,634.86
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	109,453,807.44	109,395,716.23
Including: Interests receivable		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	55,950,637.88	41,501,796.41
Including: Data resources		
Contract assets	2,708,380,363.28	2,584,975,822.49
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	62,314,633.64	64,713,930.31
Total current assets	6,629,249,323.65	6,177,196,741.89

Item	Closing balance	Opening balance
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	4,439,142,469.73	4,498,839,308.43
Other equity instruments investment	6,653,545.50	8,545,553.12
Other non-current financial assets	10,284,046,755.28	9,840,237,126.48
Investment properties	14,356,069.14	15,388,440.06
Fixed assets	1,163,500,457.01	1,188,210,085.11
Construction in progress	132,713,179.56	110,604,207.57
Productive biological assets		
Oil and gas assets		
Rights-of-use assets	384,499,710.95	408,905,731.66
Intangible assets	254,005,873.05	276,312,305.22
Including: Data resources		
Development disbursements		
Including: Data resources		
Goodwill	3,484,849,857.41	3,520,215,745.68
Long-term deferred expenses	179,801,217.93	189,282,477.31
Deferred tax assets	150,609,263.10	145,119,832.23
Other non-current assets	1,677,057,078.49	1,979,937,603.41
Total non-current assets	22,171,235,477.15	22,181,598,416.28
Total assets	28,800,484,800.80	28,358,795,158.17

Item	Closing balance	Opening balance
Current liabilities:		
Short-term borrowings	404,947,667.71	511,020,767.84
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable	6,090,170.14	5,889,386.05
Accounts payable	330,475,679.58	365,228,858.73
Advanced receipts		
Contract liabilities	1,251,417,957.21	1,079,154,504.24
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	356,208,538.15	327,858,233.53
Tax payable	205,938,183.63	231,541,815.12
Other payables	84,244,049.23	74,461,840.09
Including: Interests payable	1,567,912.20	1,388,432.36
Dividends payable	2,122,515.76	3,752,582.61
Fees and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	191,317,991.14	201,525,360.57
Other current liabilities	49,039,050.72	38,793,286.00
Total current liabilities	2,879,679,287.51	2,835,474,052.17

Item	Closing balance	Opening balance
Non-current liabilities:		
Reserve of insurance contract		
Long-term borrowings	691,647,009.48	510,560,589.95
Bonds payable	88,809,667.93	92,473,704.64
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	344,569,247.44	360,616,779.32
Long-term payables	11,980,000.00	102,518,850.00
Long-term employee benefits payable	10,172,418.98	10,897,307.43
Provisions		
Deferred revenue	15,776,161.30	16,408,677.01
Deferred tax liabilities	192,930,835.09	173,420,006.70
Other non-current liabilities		
Total non-current liabilities	1,355,885,340.22	1,266,895,915.05
Total liabilities	4,235,564,627.73	4,102,369,967.22
Owners' equity:		
Share capital	861,026,050.00	861,026,050.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital surplus	10,556,514,520.74	10,584,957,589.83
Less: Treasury shares	300,069,890.00	300,069,890.00
Other comprehensive income	-6,635,437.99	57,068,522.37
Special reserve		
Surplus reserve	436,529,393.76	436,529,393.76
General risk provision		
Retained earnings	9,369,037,969.94	9,319,994,848.81
Total equity attributable to owners of the parent	20,916,402,606.45	20,959,506,514.77
Non-controlling interests	3,648,517,566.62	3,296,918,676.18
Total owners' equity	24,564,920,173.07	24,256,425,190.95
Total liabilities and owners' equity	28,800,484,800.80	28,358,795,158.17

Legal representative:
Cao Xiaochun

*Person in charge of
accounting affairs:*
Yang Chengcheng

*Head of accounting
institution:*
Chen Xiaocui

2. Consolidated income statement

Item	<i>Unit: RMB</i>	
	Amount for the Reporting Period	Amount for the prior period
I. Total revenue	1,801,473,935.03	1,564,143,614.71
Including: Operating income	1,801,473,935.03	1,564,143,614.71
Interest income		
Premium earned		
Fees and commission income		
II. Total cost of sales	1,644,573,250.45	1,421,418,003.00
Including: Operating cost	1,321,581,301.06	1,094,382,708.37
Interest expenses		
Fees and commission expenses		
Cash surrender value		
Claim settlement expenses, net		
Net provision of insurance contract liabilities		
Policy dividend expense		
Reinsurance expenses		
Business tax and surcharge	8,559,140.98	7,028,108.21
Selling expenses	56,191,158.60	48,695,858.78
General and administrative expenses	173,425,810.23	180,487,115.67
Research and development expenses	62,655,948.12	59,075,766.11
Finance expenses	22,159,891.46	31,748,445.86
Including: Interest expenses		
Interest income		
Add: Other income	20,766,535.53	12,907,751.88
Investment income (losses are expressed by "-")	36,660,390.11	25,309,680.34
Including: Income from investment in associates and joint ventures		
Gain on derecognition of financial assets at amortized cost		
Foreign exchange gain (losses are expressed by "-")		
Net exposure hedging gain (losses are expressed by "-")		
Gain from changes in fair value (losses are expressed by "-")	195,035,877.15	-22,391,786.77
Credit impairment loss (losses are expressed by "-")	-2,488,564.14	-11,100,193.38
Asset impairment loss (losses are expressed by "-")	-572,928.54	-3,523,796.53
Gain on disposal of assets (losses are expressed by "-")	-463,466.46	577,115.15

Item	Amount for the Reporting Period	Amount for the prior period
III. Operating profit (losses are expressed by“-”)	405,838,528.23	144,504,382.40
Add: Non-operating income	133,522.92	159,536.46
Less: Non-operating expenses	27,742.70	1,038,576.02
IV. Total profits (total losses are expressed by“-”)	405,944,308.45	143,625,342.84
Less: Income tax expenses	75,860,662.83	33,644,494.98
V. Net profits (net losses are expressed by“-”)	330,083,645.62	109,980,847.86
(I) Classified by continuing operations		
1. Net profits from continuing operations (net losses are expressed by“-”)	330,083,645.62	109,980,847.86
2. Net profits from discontinued operations (net losses are expressed by“-”)		
(II) Classified by ownership of equity		
1. Net profits attributable to owners of the parent	49,043,121.13	165,468,741.43
2. Non-controlling gain or loss	281,040,524.49	-55,487,893.57
VI. Other comprehensive income, net of tax	-87,366,018.26	5,329,777.35
Other comprehensive income attributable to owners of the parent, net of tax	-63,703,960.36	5,939,283.19
(I) Items that will not be reclassified subsequently to profit or loss	-710,015.01	-169,498.32
1. Changes arising from re-measurement of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss	-710,015.01	-169,498.32
3. Change in fair value of other equity instruments investment		
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the Reporting Period	Amount for the prior period
(II) Items that may be reclassified to profit or loss	-62,993,945.35	6,108,781.51
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investments		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investments		
5. Cash flow hedge reserve		
6. Currency translation difference	-62,993,945.35	6,108,781.51
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	-23,662,057.90	-609,505.84
VII. Total comprehensive income	242,717,627.36	115,310,625.21
Total comprehensive income attributable to owners of the parent	-14,660,839.23	171,408,024.62
Total comprehensive income attributable to non-controlling interests	257,378,466.59	-56,097,399.41
VIII. Earnings per share:		
(I) Basic earnings per share	0.06	0.19
(II) Diluted earnings per share	0.06	0.19

For the business combination under common control in the current period, the net profit realized by the acquiree before the combination was RMB0.00, and the net profit realized by the acquiree in the prior period was RMB0.00.

<i>Legal representative:</i> Cao Xiaochun	<i>Person-in-charge of accounting affairs:</i> Yang Chengcheng	<i>Head of the accounting department:</i> Chen Xiaocui
---	--	--

3. Consolidated cash flow statement

<i>Unit: RMB</i>		
Item	Amount for the Reporting Period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	2,034,062,055.58	1,630,273,549.06
Net increase in customer deposits and placements from other banks		
Net increase in due to central bank		
Net increase in borrowings from other financial institutions		
Cash from premiums on original insurance contracts		
Cash received from reinsurance business, net		
Net increase in insured's deposits and investments		
Cash received from interest, fees and commissions		
Net increase in placements from banks and other financial institutions		
Net increase of funds in repurchase business		
Net cash received from customer brokerage		
Tax refunds	2,677,768.23	308,078.91
Cash receipts related to other operating activities	53,706,326.07	21,898,964.34
Sub-total of cash inflows from operating activities	2,090,446,149.88	1,652,480,592.31
Cash paid for goods and services	654,921,629.08	473,163,748.75
Net increase in loans and advances to customers		
Net increase in deposits with central bank and other banks		
Cash paid for claim settlements on original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employee benefits	811,053,535.18	772,187,943.29
Payments of all types of taxes	111,725,928.93	96,528,524.28
Cash payments related to other operating activities	195,041,280.33	112,665,761.81
Sub-total of cash outflows from operating activities	1,772,742,373.52	1,454,545,978.13
Net cash flows from operating activities	317,703,776.36	197,934,614.18

Item	Amount for the Reporting Period	Amount for the prior period
II. Cash flows from investing activities:		
Cash received from sale of investments	353,734,657.82	117,616,398.62
Cash receipts from returns on investments	118,504,208.43	31,280,078.13
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	275,166.52	34,718.30
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities		1,158.79
Sub-total of cash inflows from investing activities	472,514,032.77	148,932,353.84
Cash paid to acquire fixed assets, intangible assets and other long-term assets	50,430,337.37	48,094,554.92
Cash paid for investments	338,564,515.28	747,793,521.70
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business units	400,000.00	2,258,635.58
Cash payments related to other investing activities	28,882,924.28	8,654,880.00
Sub-total of cash outflows from investing activities	418,277,776.93	806,801,592.20
Net cash flows from investing activities	54,236,255.84	-657,869,238.36
III. Cash flows from financing activities:		
Cash receipts from capital contributions	114,736,849.16	62,600,000.00
Including: Cash receipts from capital contributions from non- controlling interests of subsidiaries		
Cash received from borrowings	234,127,700.00	555,356,000.00
Cash receipts related to other financing activities		
Sub-total of cash inflows from financing activities	348,864,549.16	617,956,000.00
Cash repayments for debts	158,269,636.30	319,007,748.00
Cash payments for distribution of dividends, profits or interest expenses	14,967,990.38	27,059,863.38
Including: Dividends and profits paid to non-controlling interests by subsidiaries		
Cash payments related to other financing activities	168,051,754.39	375,754,195.12
Sub-total of cash outflows from financing activities	341,289,381.07	721,821,806.50
Net cash flows from financing activities	7,575,168.09	-103,865,806.50

Item	Amount for the Reporting Period	Amount for the prior period
IV. Effect of change in foreign exchange rates on cash and cash equivalents	-14,454,893.77	4,959,416.33
V. Net increase in cash and cash equivalents	365,060,306.52	-558,841,014.35
Add: Cash and cash equivalents at the beginning of the period	1,722,608,377.68	2,048,493,852.84
VI. Cash and cash equivalents at the end of the period	2,087,668,684.20	1,489,652,838.49

(II) Particulars in relation to adjustments made to the financial statements as at the beginning of the year of the initial adoption of new accounting standards since 2026

Applicable Not applicable

(III) AUDIT REPORT

Whether the first-quarter financial and accounting report is audited

Yes No

The first-quarter financial and accounting report of the Company is unaudited.

The Board of Directors of Hangzhou Tigermed Consulting Co., Ltd.
April 29, 2026